#USA #San Diego #Class Action #Regeneron #fianlimab

Regeneron Pharmaceuticals Faces Legal Challenges

Investors holding shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), who suffered financial losses between August 1, 2025, and May 15, 2026, may have the opportunity to join a securities class action. This legal action, initiated by Robbins LLP, alleges that the company gave false information concerning its Phase 3 Fianlimab-Libtayo clinical trial targeting advanced melanoma patients.

Background of the Case

The lawsuit asserts that Regeneron misled investors regarding the credibility and potential success of their clinical trial. Specifically, it pertains to Fianlimab, a monoclonal antibody aimed at the LAG-3 immune checkpoint receptor on T-cells, which was studied in conjunction with Libtayo for treating advanced melanoma. The trial kicked off in mid-2022, with heightened expectations for the outcomes based on prior assurances from the company.

During the class period, Regeneron provided optimistic updates about the clinical trial, yet failed to disclose critical issues that could compromise its results. These included claims that the trial’s preliminary statistical framework was flawed, and that the treatment did not significantly outperform existing therapies. As per the complaint, investors remained unaware of the potential for the trial to miss its primary endpoint, which would compromise the investment value considerably.

Events Leading to the Securities Class Action

The class action was prompted by a series of disclosures made by Regeneron in early April and May 2026. On April 29, the company revealed during its earnings call that it had modified the Phase 3 study to expand the pool of patients eligible for analysis regarding progression-free survival (PFS). Following this news, Regeneron's stock price sharply declined from $731.77 to $686.36, a drop of around 6.2%.

The situation worsened on May 15, when Regeneron reported that its Fianlimab-Libtayo trial failed to achieve statistical significance for its primary endpoint concerning improvement in progression-free survival. This revelation led to another drop in stock price, falling from $698.25 to $629.68 within days, marking a significant decrease of approximately 9.8%.

Specific Allegations against Regeneron

The lawsuit focuses on significant omissions from Regeneron that misled investors about the clinical study. It claims the company ignored various issues, such as the unrealistic expectations set during the trial. Further, it suggests that the company’s assurances kept stock prices artificially elevated, creating a false sense of security among investors.

The trial's lack of ability to achieve its primary progression-free survival endpoint has substantial implications for investors, as it reflects ongoing viability concerns regarding the Fianlimab-Libtayo treatment method. Given these setbacks, investors argue that Regeneron’s previous positive statements were misleading and that they were not informed of the risks involved.

Who Can Participate?

Any investor who purchased Regeneron's securities during the class period and experienced losses may be eligible to participate in the class action. Potential participants are urged to pay close attention to the looming deadline of September 14, 2026, for seeking lead plaintiff status, which involves court-appointment to represent the interests of the class. While it is not essential to seek this specific title to benefit from any eventual recovery, being a lead plaintiff could enhance the investor’s involvement in the proceedings.

Notably, Robbins LLP will operate on a contingency basis, meaning investors will not incur out-of-pocket legal expenses unless there is a recovery from the lawsuit, which will cover legal fees.

Conclusion

As the legal proceedings unfold, investors should consult with financial advisors and legal experts to understand their rights and options. The outcome of this class action will likely influence not only the future of Regeneron Pharmaceuticals but could also affect shareholder confidence in the pharmaceutical sector as a whole, emphasizing the importance of transparency and disclosure in clinical trial narratives. Investors looking for updates or additional information on the lawsuit may reach out to Robbins LLP directly via their website or designated contact numbers.